Abstract
Introduction
The close association with hepatitis means that hepatocellular carcinoma (HCC)
is common in developing countries where hepatitis B and C infections are
endemic. However, the increasing prevalence of hepatitis in the West means
that incidence of HCC in the US and Europe is expected to increase
significantly over the coming years.
Scope of this report
- Overview of hepatocellular carcinoma, including epidemiology, staging,
prognosis and unmet needs
- Review of current treatment modalities and physician opinion of existing
and future treatment strategies
- Evaluation of key drugs currently used in the treatment of hepatocellular
carcinoma
- Review of late-phase drugs in development for hepatocellular carcinoma
including key opinion leaders' view on their potential
Research and analysis highlights
Typically a disease of the developing countries, incidence of HCC is
increasing in the West due to increasing cases of hepatitis infection, thus
representing a revenue opportunity for pharmaceutical and biotechnology
companies with targeted therapies.
HCC patients are poorly served by existing treatment options, with only a
small proportion amenable to curative therapy such as surgical resection and
liver transplantation. Prognosis is poor for unresectable patients, and there
remains no standard drug therapy for advanced HCC.
Given the lack of standard of care, R&D interest in HCC is relatively high,
with 37 compounds in clinical development. The majority consist of targeted
therapies, with Bayer-Schering/Onyx' s Nexavar, Genentech/Roche' s Avastin and
OSI/Genentech/Roche' s Tarceva considered to have the highest clinical and
commercial potential.
Key reasons to read this report
- Evaluate opportunities and risks in the HCC market by analyzing the
clinical and commercial potential of key pipeline drugs
- Review critical factors that drive the HCC market to assess the potential
of existing and pipeline drugs for the disease
- Understand current and future competitive dynamics of HCC to determine the
attractiveness of the market
| 
View Cart
